Thymosin Beta 4 Reverses Alzheimer's Pathology in Human Brain Organoids and Mice
Scientists identify Tβ4 as a neuroprotective factor that rescues neuronal loss and amyloid buildup in both human fAD organoids and 5xFAD mice.
Summary
Researchers at ShanghaiTech University generated familial Alzheimer's disease (fAD) brain organoids from iPSCs carrying APP mutations and used single-cell RNA sequencing to track disease-related changes. They discovered that TMSB4X, encoding thymosin beta 4 (Tβ4), was significantly downregulated in neurons of fAD organoids and in excitatory neurons of AD patients. Treating fAD organoids with Tβ4 protein rescued neuronal maturation deficits and reduced amyloid-beta accumulation. AAV-mediated overexpression of TMSB4X in 5xFAD mice similarly alleviated AD pathology and reduced neuronal hyperexcitability. These findings position Tβ4 as a promising early-intervention target for Alzheimer's disease.
Detailed Summary
Alzheimer's disease (AD) remains without a disease-modifying treatment, partly because its molecular origins in early brain development are poorly understood. This study addresses that gap by using human iPSC-derived cerebral organoids carrying familial AD (fAD) mutations—APP gene duplication (APP2) and APPV717I point mutation (HVRD)—to model early neurodevelopmental changes and identify intervention targets.
Using single-cell RNA sequencing at 30 and 60 days of organoid culture, the team identified 12 distinct cell types and found that both fAD organoid lines showed a marked reduction in mature neurons, accompanied by increased young neurons, BMP-related cells, and astrocytes—indicating impaired neuronal maturation. Immunostaining confirmed decreased TBR1 (layer VI neurons) at day 30 and NeuN (mature neurons) at day 60. Elevated β-amyloid (Aβ) immunoreactivity was observed at day 90, and soluble Aβ1-42/Aβ1-40 ratios were altered at day 60, consistent with AD cerebrospinal fluid profiles. Pseudotime trajectory analysis revealed a bifurcated neuronal differentiation path, with fAD neurons disproportionately populating an apoptotic terminal state (state 1), confirmed by elevated cleaved caspase-3 and TUNEL signals.
Cross-referencing fAD organoid DEGs with published snRNA-seq data from AD patient brains, the researchers identified TMSB4X—encoding the actin-sequestering peptide thymosin beta 4 (Tβ4)—as consistently downregulated in neurons of fAD organoids and in excitatory neurons of AD patients. This convergence across species and model systems strengthened its candidacy as a disease-relevant target. Treatment of fAD organoids with exogenous Tβ4 protein rescued the maturation deficit (restored TBR1 and NeuN levels), reduced Aβ accumulation, and decreased apoptotic signaling.
In vivo validation was performed in 5xFAD mice via intracranial AAV-TMSB4X injection to overexpress the gene in neurons. This intervention reduced amyloid plaque burden, improved neuronal survival, and mitigated neuronal hyperexcitability—a hallmark of early AD—demonstrating translational relevance beyond the organoid model.
Astrocytes in fAD organoids also displayed disease-associated astrocyte (DAA) gene signatures including elevated GSN, GFAP, CLU, and CD9, and enrichment for PI3K-Akt signaling and AD-related pathways, suggesting that glial contributions to early AD pathology are also recapitulated in this model. Overall, the study presents fAD cerebral organoids as a viable drug-discovery platform and highlights Tβ4 as a neuroprotective factor capable of modifying both developmental neurogenesis deficits and downstream AD pathology.
Key Findings
- fAD organoids show reduced mature neurons, elevated Aβ, and increased apoptosis as early as day 30–60.
- TMSB4X/Tβ4 is downregulated in neurons of fAD organoids and excitatory neurons of AD patients.
- Tβ4 protein treatment rescues neuronal maturation and reduces Aβ accumulation in fAD organoids.
- AAV-TMSB4X delivery in 5xFAD mice reduces plaques, improves neuronal survival, and lowers hyperexcitability.
- fAD astrocytes upregulate disease-associated astrocyte (DAA) markers, recapitulating glial AD features.
Methodology
Human iPSC-derived cerebral organoids with fAD mutations (APP2, APPV717I) were analyzed by scRNA-seq at days 30 and 60, with immunostaining and ELISA validation at day 90. In vivo rescue was tested via AAV-TMSB4X stereotaxic injection in 5xFAD mice, with comparison to published AD patient snRNA-seq datasets.
Study Limitations
The organoid model lacks vasculature, immune infiltration, and full brain architecture, limiting disease-stage extrapolation. Only APP-mutation fAD lines were tested; sporadic AD—the most common form—was not modeled. Mouse rescue experiments used the 5xFAD overexpression model, which may not fully reflect human AD biology.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.